The DOI matches its Crossref record; 6 of the 6 references it cites were found in a registry or an index.
Status of vaccine research and development of vaccines for herpes simplex virus
Open accessAbstract
Herpes simplex virus type-1 (HSV-1) and -2 (HSV-2) are highly prevalent global pathogens which commonly cause recurrent oral and genital ulcerations. Less common but more serious complications include meningitis, encephalitis, neonatal infection, and keratitis. HSV-2 infection is a significant driver of the HIV epidemic, increasing the risk of HIV acquisition 3 fold. As current control strategies for genital HSV-2 infection, including antiviral therapy and condom use, are only partially effective, vaccines will be required to reduce infection. Both preventive and therapeutic vaccines for HSV-2 are being pursued and are in various stages of development. We will provide an overview of efforts to develop HSV-2 vaccines, including a discussion of the clinical need for an HSV vaccine, and status of research and development with an emphasis on recent insights from trials of vaccine candidates in clinical testing. In addition, we will touch upon aspects of HSV vaccine development relevant to low and middle income countries.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Vos, T., Abajobir, A. A., Abate, K. H., Abbafati, C., Abbas, K. M., Abd-Allah, F., Abdulkader, R. S., Abdulle, A. M., Abebo, T. A., Abera, S. F., et al. (2017) · The Lancet · doi:10.1016/s0140-6736(17)32154-2 · Cited by 13,220
A Vaccine to Prevent Herpes Zoster and Postherpetic Neuralgia in Older Adults
Oxman, M. N., Levin, M. J., Johnson, G. R., Schmader, K. E., Straus, S. E., Gelb, L. D., Arbeit, R. D., Simberkoff, M. S., Gershon, A. A., Davis, L. E., et al. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa051016 · Cited by 2,412
Quadrivalent vaccine against human papillomavirus to prevent anogenital diseases
Garland, S. M., Hernandez-Avila, M., Wheeler, C. M., Perez, G., Harper, D. M., Leodolter, S., Tang, G. W. K., Ferris, D. G., Steben, M., Bryan, J., et al. (2007) · New England Journal of Medicine · doi:10.1056/nejmoa061760 · Cited by 1,886
Once-daily valacyclovir to reduce the risk of transmission of genital herpes.
Corey, L., Wald, A., Patel, R., Sacks, S. L., Tyring, S. K., Warren, T., Douglas, J. M., Paavonen, J., Morrow, R. A., Beutner, K. R., et al. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa035144 · Cited by 720
Self-citationOwusu-Edusei, K., Chesson, H. W., Gift, T. L., Tao, G., Mahajan, R., Ocfemia, M. C. B., & Kent, C. K. (2013) · Sexually Transmitted Diseases · doi:10.1097/olq.0b013e318285c6d2 · Cited by 452 · cited 1×
“In the United States, HSV-2 infection is estimated to have a total lifetime cost of $540 million US dollars (adjusted to 2010 dollars), behind only HIV and HPV in costs among 8 major STIs [17 .”
Masese, L., Baeten, J. M., Richardson, B. A., Bukusi, E., John-Stewart, G., Graham, S. M., Shafi, J., Kiarie, J., Overbaugh, J., & McClelland, R. S. (2015) · AIDS · doi:10.1097/qad.0000000000000646 · Cited by 70
Cited by
Herpes Simplex Virus-1 Encephalitis in Adults: Pathophysiology, Diagnosis, and Management
Bradshaw, M. J., & Venkatesan, A. (2016) · Neurotherapeutics · doi:10.1007/s13311-016-0433-7 · Cited by 492
Looker, K. J., Elmes, J. A. R., Gottlieb, S. L., Schiffer, J. T., Vickerman, P., Turner, K. M. E., & Boily, M.-C. (2017) · The Lancet Infectious Diseases · doi:10.1016/s1473-3099(17)30405-x · Cited by 300
Self-citationTorrone, E. A., Morrison, C. S., Chen, P.-L., Kwok, C., Francis, S. C., Hayes, R. J., Looker, K. J., McCormack, S., McGrath, N., van de Wijgert, J. H. H. M., et al. (2018) · PLOS Medicine · doi:10.1371/journal.pmed.1002511 · Cited by 256
Self-citation
Metadata
- Authors
- Johnston, C., Gottlieb, S. L., & Wald, A.
- Venue
- Vaccine
- Publisher
- Elsevier BV
- Published
- 2016-06
- Volume
- 34
- Issue
- 26
- Pages
- 2948-2952
- ISSN
- 0264-410X (ISSN-L)
- OpenAlex
- W2409598223
- Cited by
- 166
- References
- 6
- FWCI
- 16.90
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Status of vaccine research and development of vaccines for herpes simplex virus. https://app.cochat.ai/papers/10.1016/j.vaccine.2015.12.076
- The paper
- Johnston, C., Gottlieb, S. L., & Wald, A. (2016). Status of vaccine research and development of vaccines for herpes simplex virus. Vaccine. https://doi.org/10.1016/j.vaccine.2015.12.076
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.